OverviewSuggest Edit

ImpediMed is engaged in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. The Company's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor.

TypePublic
Founded1999
HQPinkenba, AU
Websiteimpedimed.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Feb 2019)68
Revenue (FY, 2018)$5.2 M(-14%)
Share Price (Sept 2021)$0.1
Cybersecurity ratingAMore

Key People/Management at ImpediMed

Richard Carreon

Richard Carreon

Managing Director & Chief Executive Officer
Frank Vicini

Frank Vicini

Chief Medical Officer
Timothy Cruickshank

Timothy Cruickshank

EVP Finance and Acting CFO
Shashi Tripathi

Shashi Tripathi

Chief Technology Officer
Catherine Kingsford

Catherine Kingsford

SVP Medical Affairs
Dennis Schlaht

Dennis Schlaht

SVP R&D and Technology
Show more

ImpediMed Office Locations

ImpediMed has offices in Pinkenba and Carlsbad
Pinkenba, AU (HQ)
Unit 1 50 Parker Ct
Carlsbad, CA, US
5900 Pasteur Ct #125
Show all (2)

ImpediMed Financials and Metrics

ImpediMed Revenue

Embed Graph
View revenue for all periods
ImpediMed's revenue was reported to be $5.23 m in FY, 2018 which is a 14.8% decrease from the previous period.
USD

Revenue (FY, 2018)

5.2m

Revenue growth (FY, 2017 - FY, 2018), %

(14.8%)

Gross profit (FY, 2018)

3.6m

Gross profit margin (FY, 2018), %

69.5%

Net income (FY, 2018)

(27.2m)

EBIT (FY, 2018)

(27.1m)

Market capitalization (9-Sept-2021)

186.5m

Closing stock price (9-Sept-2021)

0.1

Cash (30-Jun-2018)

31.3m
ImpediMed's current market capitalization is $186.5 m.
USDFY, 2017FY, 2018

Revenue

6.1m5.2m

Revenue growth, %

(15%)

Cost of goods sold

1.5m1.6m

Gross profit

4.6m3.6m
USDFY, 2017FY, 2018

Cash

54.9m31.3m

Accounts Receivable

3.8m4.3m

Inventories

1.5m1.8m

Current Assets

61.3m37.8m
USDFY, 2017FY, 2018

Cash From Operating Activities

(25.6m)(23.5m)

Purchases of PP&E

(335.0k)(155.0k)

Cash From Investing Activities

(362.0k)(1.2m)

Cash From Financing Activities

720.0k256.0k
USDFY, 2017

Revenue/Employee

80.7k

Financial Leverage

1.1 x
Show all financial metrics

ImpediMed Revenue Breakdown

Embed Graph

ImpediMed revenue breakdown by business segment: 75.5% from Medical and 24.5% from Test& Measurement

ImpediMed revenue breakdown by geographic segment: 24.4% from Australia/ROW and 75.6% from North America

ImpediMed Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

ImpediMed Online and Social Media Presence

Embed Graph

ImpediMed News and Updates

ImpediMed Announces Ambitious New Program Aimed at Ending Cancer-Related Lymphedema

CARLSBAD, Calif. and BRISBANE, Australia, Oct. 23, 2019 /PRNewswire/ -- ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), today announces the...

ImpediMed Blogs

Lacey Drug Company

Time-to-Decongestion Following Heart Failure Hospitalization as Measured by Extracellular Fluid Nadir Using Bioimpedance Spectroscopy

The time required to achieve clinical decongestion is highly variable and often takes longer than may be anticipated; in our study it took an average of 16.9 days. Our results show that ECF is more sensitive than weight when tracking post-discharge decongestion. Noninvasive BIS measurements may assi…
Show more

ImpediMed Frequently Asked Questions

  • When was ImpediMed founded?

    ImpediMed was founded in 1999.

  • Who are ImpediMed key executives?

    ImpediMed's key executives are Richard Carreon, Frank Vicini and Timothy Cruickshank.

  • How many employees does ImpediMed have?

    ImpediMed has 68 employees.

  • What is ImpediMed revenue?

    Latest ImpediMed annual revenue is $5.2 m.

  • What is ImpediMed revenue per employee?

    Latest ImpediMed revenue per employee is $76.8 k.

  • Who are ImpediMed competitors?

    Competitors of ImpediMed include BrainWaveBank, Raziel Health and HUMAN.

  • Where is ImpediMed headquarters?

    ImpediMed headquarters is located at Unit 1 50 Parker Ct, Pinkenba.

  • Where are ImpediMed offices?

    ImpediMed has offices in Pinkenba and Carlsbad.

  • How many offices does ImpediMed have?

    ImpediMed has 2 offices.